• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

临床实施和验证基于下一代测序的癌症检测的自动化人类基因组变异协会 (HGVS) 命名系统。

Clinical Implementation and Validation of Automated Human Genome Variation Society (HGVS) Nomenclature System for Next-Generation Sequencing-Based Assays for Cancer.

机构信息

Division of Molecular and Genomic Pathology, Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.

Division of Molecular and Genomic Pathology, Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; Informatics Subdivision Leadership, Association for Molecular Pathology, Bethesda, Maryland.

出版信息

J Mol Diagn. 2018 Sep;20(5):628-634. doi: 10.1016/j.jmoldx.2018.05.006. Epub 2018 Jun 21.

DOI:10.1016/j.jmoldx.2018.05.006
PMID:29936258
Abstract

Human Genome Variation Society (HGVS) nomenclature is a de facto clinical standard for reporting DNA sequence variants. With increasing use of high-throughput sequencing, manual generation of HGVS nomenclatures for all variants is impractical and error-prone. It is therefore beneficial to include one or more HGVS generator tools in next-generation sequencing (NGS) bioinformatics pipelines to enable automated, consistent, and accurate generation of HGVS nomenclature after appropriate validation. The authors implemented an HGVS nomenclature tool, the hgvs package, by integrating it into their custom-developed NGS variant management and reporting software. Use of Docker containers provided a strategic advantage to the integration process. Clinical implementation of the hgvs package was validated using a cohort of 330 variants that appropriately represented cancer-related genes and clinically important variant types. The hgvs package was able to generate HGVS-compliant variant nomenclature (both c. and p.) for 308 of the 330 (93.3%) variants, including all those in the coding and untranslated regions, and 32 of 35 (91.4%) in the consensus splice site region. Discrepant HGVS nomenclature involved variants in the intronic (16 of 40) and consensus splice site (3 of 35) regions with repeat sequences. Overall, implementation of the hgvs package in the clinical NGS workflow improved consistency and accuracy of reporting HGVS nomenclature.

摘要

人类基因组变异协会 (HGVS) 命名法是报告 DNA 序列变异的事实上的临床标准。随着高通量测序的应用越来越广泛,为所有变体手动生成 HGVS 命名法既不切实际又容易出错。因此,在下一代测序 (NGS) 生物信息学管道中包含一个或多个 HGVS 生成器工具,以在适当验证后实现 HGVS 命名法的自动化、一致性和准确性生成,这是有益的。作者通过将 hgvs 包集成到他们自己开发的 NGS 变体管理和报告软件中,实现了一个 HGVS 命名法工具。使用 Docker 容器为集成过程提供了战略优势。使用 330 个变体的队列验证了 hgvs 包的临床实施,这些变体适当代表了与癌症相关的基因和临床上重要的变体类型。hgvs 包能够为 330 个变体中的 308 个 (93.3%) 生成符合 HGVS 标准的变体命名法 (c. 和 p.),包括编码和非翻译区的所有变体,以及共识剪接位点区的 32 个 (91.4%)。不一致的 HGVS 命名法涉及具有重复序列的内含子 (40 个中的 16 个) 和共识剪接位点 (35 个中的 3 个) 区域的变体。总体而言,在临床 NGS 工作流程中实施 hgvs 包提高了报告 HGVS 命名法的一致性和准确性。

相似文献

1
Clinical Implementation and Validation of Automated Human Genome Variation Society (HGVS) Nomenclature System for Next-Generation Sequencing-Based Assays for Cancer.临床实施和验证基于下一代测序的癌症检测的自动化人类基因组变异协会 (HGVS) 命名系统。
J Mol Diagn. 2018 Sep;20(5):628-634. doi: 10.1016/j.jmoldx.2018.05.006. Epub 2018 Jun 21.
2
hgvs: A Python package for manipulating sequence variants using HGVS nomenclature: 2018 Update.HGVS:使用 HGVS 命名法操作序列变异的 Python 包:2018 更新。
Hum Mutat. 2018 Dec;39(12):1803-1813. doi: 10.1002/humu.23615. Epub 2018 Sep 5.
3
A Python package for parsing, validating, mapping and formatting sequence variants using HGVS nomenclature.一个用于使用HGVS命名法解析、验证、映射和格式化序列变异的Python软件包。
Bioinformatics. 2015 Jan 15;31(2):268-70. doi: 10.1093/bioinformatics/btu630. Epub 2014 Sep 30.
4
Describing structural changes by extending HGVS sequence variation nomenclature.通过扩展 HGVS 序列变异命名法来描述结构变化。
Hum Mutat. 2011 May;32(5):507-11. doi: 10.1002/humu.21427. Epub 2011 Mar 15.
5
Variation in nomenclature of somatic variants for selection of oncological therapies: Can we reach a consensus soon?肿瘤治疗选择中体变异命名法的变化:我们能否尽快达成共识?
Hum Mutat. 2020 Jan;41(1):7-16. doi: 10.1002/humu.23926. Epub 2019 Oct 14.
6
Sequence Variant Descriptions: HGVS Nomenclature and Mutalyzer.序列变异描述:HGVS命名法与Mutalyzer
Curr Protoc Hum Genet. 2016 Jul 1;90:7.13.1-7.13.19. doi: 10.1002/cphg.2.
7
VariantValidator: Accurate validation, mapping, and formatting of sequence variation descriptions.VariantValidator:准确验证、映射和格式化序列变异描述。
Hum Mutat. 2018 Jan;39(1):61-68. doi: 10.1002/humu.23348. Epub 2017 Oct 17.
8
A common classification framework for histone sequence alterations in tumours: an expert consensus proposal.肿瘤中组蛋白序列改变的常见分类框架:专家共识建议。
J Pathol. 2021 Jun;254(2):109-120. doi: 10.1002/path.5666. Epub 2021 May 7.
9
Describing Sequence Variants Using HGVS Nomenclature.使用人类基因组变异协会(HGVS)命名法描述序列变异。
Methods Mol Biol. 2017;1492:243-251. doi: 10.1007/978-1-4939-6442-0_17.
10
CSN and CAVA: variant annotation tools for rapid, robust next-generation sequencing analysis in the clinical setting.CSN和CAVA:用于临床环境中快速、可靠的下一代测序分析的变异注释工具。
Genome Med. 2015 Jul 28;7(1):76. doi: 10.1186/s13073-015-0195-6.

引用本文的文献

1
Network analysis of NRG1 variants of uncertain significance (VUSes) in advanced non-small-cell lung cancer and their prognostic role in EGFR-mutant patients treated with first-line osimertinib.晚期非小细胞肺癌中意义未明的NRG1变异体(VUSes)的网络分析及其在一线使用奥希替尼治疗的EGFR突变患者中的预后作用。
ESMO Open. 2025 Aug 29;10(9):105556. doi: 10.1016/j.esmoop.2025.105556.
2
An ontology-based rare disease common data model harmonising international registries, FHIR, and Phenopackets.一种基于本体的罕见病通用数据模型,用于协调国际登记处、FHIR和表型数据包。
Sci Data. 2025 Feb 8;12(1):234. doi: 10.1038/s41597-025-04558-z.
3
Recommendations for reporting tissue and circulating tumour (ct)DNA next-generation sequencing results in non-small cell lung cancer.
非小细胞肺癌中组织和循环肿瘤(ct)DNA 下一代测序结果报告的建议。
Br J Cancer. 2024 Jul;131(2):212-219. doi: 10.1038/s41416-024-02709-4. Epub 2024 May 15.
4
A systematic overview of rare disease patient registries: challenges in design, quality management, and maintenance.罕见病患者登记处的系统综述:设计、质量管理和维护方面的挑战。
Orphanet J Rare Dis. 2023 May 5;18(1):106. doi: 10.1186/s13023-023-02719-0.
5
A performance evaluation study: Variant annotation tools - the enigma of clinical next generation sequencing (NGS) based genetic testing.一项性能评估研究:变异注释工具——基于临床下一代测序(NGS)的基因检测之谜
J Pathol Inform. 2022 Jul 28;13:100130. doi: 10.1016/j.jpi.2022.100130. eCollection 2022.
6
A new hybrid record linkage process to make epidemiological databases interoperable: application to the GEMO and GENEPSO studies involving BRCA1 and BRCA2 mutation carriers.一种新的混合记录链接过程,使流行病学数据库具有互操作性:在涉及 BRCA1 和 BRCA2 突变携带者的 GEMO 和 GENEPSO 研究中的应用。
BMC Med Res Methodol. 2021 Jul 29;21(1):155. doi: 10.1186/s12874-021-01299-6.
7
Variation in nomenclature of somatic variants for selection of oncological therapies: Can we reach a consensus soon?肿瘤治疗选择中体变异命名法的变化:我们能否尽快达成共识?
Hum Mutat. 2020 Jan;41(1):7-16. doi: 10.1002/humu.23926. Epub 2019 Oct 14.